A NARRATIVE REVIEW OF THE ANTI-SARS-COV2 MONOCLONAL ANTIBODIES COCKTAIL – CASIRIVIMAB PLUS IMDEVIMAB FOR SARS-COV2 INFECTION
AbstractNumerous therapeutic and prophylactic interventions are tried being developed and tried for COVID-19, from repurposed drugs, antivirals to immunotherapy including convalescent serum, vaccines and monoclonal antibodies to reduce the global burden of the disease. Vaccine-derived immunity develops over time and remains as the primary option for prophylaxis. Administration of neutralizing mAbs is an immediate and passive immunotherapy with the potential to reduce disease progression, hospitalizations and death. Antibody-based treatments are likely to be more effective if used during the early phase of the illness. Casarivimab together with Imdevimab, holds emergency use authorizations in several countries globally and in India. This review discusses the mechanism of action, current clinical indications, dose, use with other medications and vaccines, duration of protection, protection against variants and evidence of Casarivimab and Imdevimab monoclonal antibody cocktail therapy for mild to moderate COVID-19 patients.
Article Information
3
4297-4304
515 KB
436
English
IJPSR
Maria Jose, Sasmi M. B and Praveenlal Kuttichira
Department of Pharmacology, Government Medical College, Manjeri, Kerala, India.
sasmianuraj@gmail.com
23 February 2022
27 April 2022
02 May 2022
10.13040/IJPSR.0975-8232.13(11).4297-04
01 November 2022
Download